Preimplantation Genetic Testing Market Industry Development Scenario and Forecast to 2022

Posted on 2019-09-04 by Mark Hub in Healthcare // 0 Comments

The preimplantation genetic testing market is likely to witness steady growth over the course of the forecast period. Preimplantation genetic testing is the procedure of testing embryos to identify genetic diseases or defects before implantation. Along with implantation of healthy embryo which results in the genetically healthy baby, the preimplantation genetic testing is done to eliminate the risk of structural chromosome abnormalities, Mendelian disorders, etc. However, preimplantation genetic testing also carries various risks such as multiple pregnancy, birth defects, ovarian hyperstimulation syndrome. Hence, researchers are focusing on developing new technology and methods that can minimize all the possible risks related with the preimplantation genetic testing.

Get Report Sample Copy @ https://www.factmr.com/connectus/sample?flag=S&rep_id=292

The preimplantation genetic testing market is likely to be influenced by a combination of macroeconomic and microeconomic factors. Due to the changing lifestyle, increasing number of people are suffering from genetic disorders or diseases. Hence there has been a significant demand growth in preimplantation genetic testing. The preimplantation genetic testing is also gaining traction for diagnosing minor disabilities and other serious diseases such as cancer. Researchers are also focusing on using innovative techniques for eliminating the possibility of embryo destruction while preimplantation genetic testing.

According to the latest report by Fact.MR, the preimplantation genetic testing market is expected to experience strong growth. The preimplantation genetic testing market is estimated to reach US$ 575.0 million revenue by 2022 end. Due to the increasing awareness of preimplantation genetic testing to avoid genetic disorders, the rise in a number of healthcare providers and healthcare institutes providing preimplantation genetic testing are the influencing factors contributing to growth of preimplantation genetic testing market.

Market Taxonomy

Test Type	End User	Application	Technology
Genetic Diagnosis	Hospitals	Embryo HLA Typing for Stem Cell Therapy	NGS
Genetic Screening	Diagnostic Labs	IVF Prognosis	PCR
	Research & Academic Institutes	Late-Onset Genetic Disorders	FISH
	Specialized Clinics	Inherited Genetic Disease	CGH
	Other End Users	Other Applications	SNP

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

Genetic Screening to Emerge as the Highly Preferred Test Type

Genetic screening is expected to be the highly preferred preimplantation genetic testing as compared to genetic diagnosis. Gaining nearly two-third of the preimplantation genetic testing market share in terms of revenue towards 2017 end, genetic screening is estimated to create more than US$ 100 million incremental opportunity throughout the forecast period.

Browse Complete Research report with TOC @ https://www.factmr.com/report/292/preimplantation-genetic-testing-market

Among all other end users of preimplantation genetic testing, specialized clinics are expected to experience strong growth. Specialized clinics are estimated to exceed US$ 200 million revenue towards 2022 end. Meanwhile, hospitals are also expected to witness impressive growth in preimplantation genetic testing market.

Preimplantation Genetic Testing to find Largest Application in Embryo HLA Typing for Stem Cell Therapy

Embryo HLA typing for stem cell therapy is expected to show healthy growth from throughout 2017-2022. Embryo HLA typing for stem cell therapy is estimated to create an incremental opportunity exceeding US$ 70 million during 2017-2022.

NGS Technology to Gain Maximum Traction in the Preimplantation Genetic Testing Market

Compared to the various other technologies, NGS is expected to be the technology gaining highest revenue share in the preimplantation genetic testing market. NGS is estimated to exceed US$ 200 million revenue by 2022 end.

Competition Tracking

The report also profiles companies operating in the preimplantation genetic testing market, which include Agilent Technologies Inc., Abbott Laboratories, CooperSurgical Inc., Oxford Gene Technology IP, Illumina, Inc., Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Genea Limited, Natera, Inc., Rubicon Genomics, Inc., and CombiMatrix Corporation.

Send an enquiry @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=292

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Matched content

Editor’s pick